Lighting up PNETs: Creating Murine Models with a Novel Bioluminescent Cell Line

Area of Science:

• Oncology
• Preclinical Research
• Molecular Biology

Background:

• Pancreatic neuroendocrine tumors (PNETs) are rare and have limited treatment options, especially in advanced stages.
• PNETs exhibit significant biological heterogeneity driven by complex molecular pathways.
• There is a need for effective preclinical models for real-time monitoring of PNET progression.

Purpose of the Study:

• To engineer a novel, dual-labeled murine cell line for PNET research.
• To evaluate different implantation sites for a PNET preclinical model.
• To establish a biologically relevant platform for studying PNETs.

Main Methods:

• Engineered STC-1 murine cells to co-express firefly luciferase (F-Luc) and enhanced green fluorescent protein (EGFP).
• Implanted dual-labeled cells into immunocompromised mice via subcutaneous (SubQ), renal capsule (RC), and orthotopic pancreatic (OP) routes.
• Tracked tumor growth using bioluminescence imaging and assessed PNET characteristics via histological and immunohistochemical analyses.

Main Results:

• All three models formed tumors, but SubQ and RC models showed limited PNET features.
• The orthotopic pancreatic (OP) model demonstrated robust growth and closely resembled human PNETs.
• Lineage tracing in the OP model revealed clonal architecture and dynamic tumor progression.

Conclusions:

• The orthotopic pancreatic implantation of dual-labeled STC-1 cells is a valuable preclinical model for PNETs.
• This model closely mimics human PNETs, offering utility for biological investigation.
• The platform supports the evaluation of novel therapeutic strategies for PNETs.